Mitochondrial Dysfunction Hub

Migration, Crosslink

📖

Mitochondrial Dysfunction Hub

active

wiki page Created: 2026-04-02T07:19:51 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-mitochondrial-dysfunctio

📖 Wiki Page

mechanism2556 wordssynced 2026-04-02

Mitochondrial Dysfunction Hub

Overview

This hub serves as the central navigation point for all mitochondrial dysfunction content in NeuroWiki. Mitochondrial dysfunction is one of the most consistently observed pathological features across neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Huntington's disease](/mechanisms/huntington-pathway), and the [tauopathies](/diseases/corticobasal-degeneration) including [CBS/PSP](/diseases/progressive-supranuclear-palsy).

The brain, comprising approximately 2% of body mass but consuming ~20% of oxygen and glucose, is exquisitely vulnerable to mitochondrial disruptions. Neurons are particularly susceptible due to their post-mitotic nature, high metabolic demands, and limited glycolytic capacity[@guzman2024].

Pathophysiological Mechanisms

Electron Transport Chain Defects

The electron transport chain (ETC) is the primary site of mitochondrial dysfunction across neurodegenerative diseases. Complex I (NADH:ubiquinone oxidoreductase) deficiency is the most consistently observed abnormality, particularly in [Parkinson's disease](/diseases/parkinsons-disease)[@schapira2020]. Multiple mechanisms contribute to ETC dysfunction:

Complex I deficiency:

Rotenone and MPTP exposure recapitulate PD features in models
PINK1 and PARK2 mutations impair Complex I function
mtDNA mutations affect Complex I subunits
Post-translational modifications (oxidation, nitration) impair activity

...

Mitochondrial Dysfunction Hub

Overview

This hub serves as the central navigation point for all mitochondrial dysfunction content in NeuroWiki. Mitochondrial dysfunction is one of the most consistently observed pathological features across neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Huntington's disease](/mechanisms/huntington-pathway), and the [tauopathies](/diseases/corticobasal-degeneration) including [CBS/PSP](/diseases/progressive-supranuclear-palsy).

The brain, comprising approximately 2% of body mass but consuming ~20% of oxygen and glucose, is exquisitely vulnerable to mitochondrial disruptions. Neurons are particularly susceptible due to their post-mitotic nature, high metabolic demands, and limited glycolytic capacity[@guzman2024].

Pathophysiological Mechanisms

Electron Transport Chain Defects

The electron transport chain (ETC) is the primary site of mitochondrial dysfunction across neurodegenerative diseases. Complex I (NADH:ubiquinone oxidoreductase) deficiency is the most consistently observed abnormality, particularly in [Parkinson's disease](/diseases/parkinsons-disease)[@schapira2020]. Multiple mechanisms contribute to ETC dysfunction:

Complex I deficiency:

Rotenone and MPTP exposure recapitulate PD features in models
PINK1 and PARK2 mutations impair Complex I function
mtDNA mutations affect Complex I subunits
Post-translational modifications (oxidation, nitration) impair activity

Complex III and IV defects:

Accumulation of damaged mtDNA affects complex assembly
Amyloid-beta directly inhibits Complex IV in [Alzheimer's disease](/diseases/alzheimers-disease)
Tau pathology disrupts mitochondrial transport to synapses[@jiang2024]

Reactive Oxygen Species and Oxidative Stress

Mitochondrial dysfunction leads to excessive reactive oxygen species (ROS) production, creating a vicious cycle of oxidative damage[@johri2023]:

ROS sources in neurodegeneration:

Electron leak from Complex I and III
Monoamine oxidase activity in dopaminergic neurons
Iron accumulation in substantia nigra
Inflammatory glial cell activation

Consequences of oxidative stress:

Lipid peroxidation (malondialdehyde, 4-hydroxynonenal)
Protein oxidation (carbonylation, nitration)
mtDNA mutations and deletions
Activation of cell death pathways

Calcium Dysregulation

Mitochondria serve as critical calcium buffers, and their dysfunction disrupts cellular calcium homeostasis[@gandhi2023]:

Calcium handling defects:

Impaired mitochondrial calcium uptake (mCU/MCU)
Reduced calcium extrusion (mNCLX)
Altered mitochondrial permeability transition pore (mPTP)
Disrupted calcium signaling to nucleus

Impact on neuronal function:

Excitotoxicity through NMDA receptor overactivation
Calpain activation and proteolysis
Impaired synaptic plasticity
Activation of apoptotic pathways

Mitochondrial DNA Damage

The brain accumulates mtDNA mutations with aging, and this burden is amplified in neurodegenerative diseases[@mittal2023]:

mtDNA alterations in neurodegeneration:

Point mutations and deletions in neurons
Reduced mtDNA copy number
Impaired mtDNA repair (base excision repair defects)
3243A>G mutation in MELAS syndrome with parkinsonism

Metabolic Vulnerability of Specific Neuron Types

Different neuronal populations show varying susceptibility to mitochondrial dysfunction[@wang2024]:

Dopaminergic neurons:

High metabolic demand for dopamine synthesis
Complex I deficiency in substantia nigra
Iron accumulation promoting oxidative stress
Limited antioxidant capacity

Cortical pyramidal neurons:

Large axonal arbors requiring extensive mitochondria
Amyloid-beta and tau impact on mitochondrial transport
High calcium influx during synaptic activity

Therapeutic Approaches

Mitochondrial-Targeted Interventions

Multiple therapeutic strategies aim to restore mitochondrial function:

Antioxidants:

Coenzyme Q10 (electron carrier and antioxidant)
MitoQ (mitochondria-targeted ubiquinone)
MitoTEMPO (mitochondria-targeted superoxide dismutase mimetic)
Vitamin E and N-acetylcysteine

Metabolic support:

Alpha-lipoic acid (energy metabolism cofactor)
Creatine (ATP buffer)
Pyruvate dehydrogenase activators
Ketone supplementation

Quality control enhancement:

PINK1-Parkin pathway activators
Autophagy inducers (rapamycin, metformin)
Mitochondrial dynamics modulators
mitochondrial-derived vesicle targeting

Emerging Therapies

Pharmacological approaches:

PGC-1alpha agonists for mitochondrial biogenesis
SIRT1/3 activators for metabolic regulation
mTOR inhibitors for autophagy enhancement
GLP-1 receptor agonists with mitochondrial effects

Gene therapy:

Mitochondrial-targeted gene delivery
MT-ND genes for Complex I restoration
TFAM for mtDNA maintenance
PINK1/PARK2 expression optimization

Cell-based approaches:

Mitochondrial transplantation
Stem cell-derived neuronal replacement
Mitochondrial-rich extracellular vesicles

Mouse Models of Mitochondrial Dysfunction

Genetic Models

PD models:

PINK1 knockout mice (subtle phenotype without stress)
PARK2 knockout mice (age-related dopaminergic loss)
PINK1/PARK2 double knockout (robust degeneration)
Mitochondrial DNA mutation models

AD models:

3xTg-AD (APP, Tau, PS1 mutations)
APP/PS1 models (amyloid-driven mitochondrial dysfunction)
Tau P301L models (tau pathology effects)
mtDNA mutator mice (accelerated aging)[@shen2024]

ALS models:

SOD1 G93A transgenic mice
TDP-43 transgenic models
C9orf72 BAC models

Toxin Models

MPTP (Complex I inhibitor) — acute and chronic models
Rotenone (Complex I inhibitor) — systemic model
6-OHDA (dopaminergic toxin)
Kainic acid (excitotoxic model)
Chronic mild stress models

Limitations

Species differences in mitochondrial biology
Incomplete recapitulation of human disease
Strain-dependent phenotypes
Environmental factor interactions

Biomarkers of Mitochondrial Dysfunction

Fluid Biomarkers

Blood markers:

Mitochondrial DNA copy number
Circulating mtDNA fragments
Cell-free mitochondrial peptides
Mitochondrial-derived vesicles

CSF markers:

Mitochondrial proteins (TFAM, COXVIII)
Lactate and pyruvate
Neurofilament light chain (NfL)
Mitochondrial-specific metabolites

Imaging Biomarkers

PET ligands for mitochondrial function
MR spectroscopy (lactate, N-acetylcysteine)
Diffusion MRI (neuronal integrity)
Mito-Tagging approaches

Functional Assessments

Seahorse XF analysis (cellular respirometry)
ATP:ADP ratios
Membrane potential measurements
Calcium handling assays

Key Genes in Mitochondrial Dysfunction

PINK1 — PTEN Induced Kinase 1

[PINK1](/genes/pink1) (PTEN Induced Kinase 1) is a serine/threonine-protein kinase localized to the outer mitochondrial membrane. It acts as a master regulator of mitophagy, accumulating on damaged mitochondria to recruit [Parkin](/genes/park2) for degradation.

Key function: Mitochondrial quality control sensor — stabilizes on damaged mitochondria and phosphorylates ubiquitin and Parkin to trigger mitophagy.

Location: 1p36.12
OMIM: 608309
[View gene page →](/genes/pink1)

PARK2 — Parkin RBR E3 Ubiquitin Protein Ligase

[PARK2](/genes/park2) encodes Parkin, a RING-between-RING (RBR) family E3 ubiquitin ligase. Together with PINK1, it forms the PINK1-Parkin mitophagy pathway — one of the best-characterized mitochondrial quality control mechanisms.

Key function: Ubiquitin ligase that tags damaged mitochondria for autophagic degradation.

Location: 6q26
OMIM: 602544
[View gene page →](/genes/park2)

ATP13A2 — ATPase 13A2

[ATP13A2](/genes/atp13a2) encodes a lysosomal P5-type ATPase that is critical for mitochondrial function and autophagy. Mutations cause Kufor-Rakeb syndrome, a form of early-onset parkinsonism with dementia.

Key function: Lysosomal cation transporter — supports mitochondrial quality control through lysosomal function.

Location: 1p36
OMIM: 610513
[View gene page →](/genes/atp13a2)

TFAM — Mitochondrial Transcription Factor A

[TFAM](/genes/tfam) is essential for mitochondrial DNA replication, transcription, and repair. It packages mtDNA into nucleoids and regulates mtDNA copy number.

Key function: Mitochondrial genome maintenance — controls mtDNA transcription, replication, and repair.

Location: 10q21
OMIM: 604933
[View gene page →](/genes/tfam)

OPA1 — Optic Atrophy 1

OPA1 is a dynamin-related GTPase critical for mitochondrial inner membrane fusion. It maintains cristae structure and promotes mitochondrial DNA stability.

Key function: Mitochondrial inner membrane fusion — maintains cristae integrity and prevents apoptosis.

Location: 3q28-q29
OMIM: 605290

Mitochondrial Quality Control Pathways

Mitophagy Pathways

The PINK1-Parkin pathway is the best-characterized mitochondrial quality control mechanism[@taylor2023]:

Mechanism:

PINK1 accumulates on damaged mitochondria (outer membrane)

PINK1 phosphorylates ubiquitin and Parkin

Parkin ubiquitinates mitochondrial proteins

Autophagy receptors (p62, OPTN, NDP52) recruit autophagosomes

Lysosomal fusion degrades damaged mitochondria

Mermaid diagram (expand to render)

Other mitophagy pathways:

BNIP3/NIX-mediated mitophagy (hypoxia-induced)
FUNDC1 receptor-mediated mitophagy
Atg32-mediated mitophagy in yeast models
Lipid-mediated recruitment (cardiolipin externalization)

Key mechanism pages:

[Mitophagy Pathway](/mechanisms/mitophagy) — Detailed mitophagy mechanisms
[PINK1-Parkin Pathway](/mechanisms/pink1-parkin-pathway) — PINK1-Parkin specific pathway
[Mitochondrial Quality Control Network](/mechanisms/mitochondrial-quality-control-network-pathway) — Overview of quality control

Mitochondrial Dynamics

Fusion and fission balance determines mitochondrial morphology and function[@pickrell2021]:

Fusion machinery:

OPA1 (inner membrane fusion)
MFN1, MFN2 (outer membrane fusion)
Mitochondrial DNA mixing
Protein complementation

Fission machinery:

DRP1 (dynamin-related protein 1)
FIS1, MFF, MiD49/50 (receptors)
Post-fission quality control

Mermaid diagram (expand to render)

Disease implications:

OPA1 mutations cause autosomal dominant optic atrophy
DRP1 deficits impair mitochondrial quality control
MFN2 deficiency in Charcot-Marie-Tooth disease
Dynamics imbalance in AD, PD, HD["@pal2023"]

Key mechanism pages:

[Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics) — Fusion and fission overview
[Mitochondrial Fusion](/mechanisms/mitochondrial-fusion-neurodegeneration) — Fusion mechanisms
[Mitochondrial Fission](/mechanisms/mitochondrial-fission-neurodegeneration) — Fission mechanisms

Mitochondrial Biogenesis

New mitochondria formation through PGC-1alpha signaling[@vinayagam2023]:

Regulators:

PGC-1alpha (master regulator)
NRF1, NRF2 (transcription factors)
ERRalpha (estrogen-related receptor)
TFAM (mitochondrial transcription factor)

Pathways:

AMPK activation (energy sensing)
SIRT1 deacetylation (metabolic regulation)
mTOR inhibition (nutrient sensing)
[Mitochondrial Biogenesis in Neurodegeneration](/mechanisms/mitochondrial-biogenesis-neurodegeneration) — New mitochondria formation

Mitochondrial-Derived Vesicles

Alternative quality control through MDV formation[@bader2023]:

MDV pathways:

PINK1-dependent MDV trafficking to lysosomes
Parkin-independent vesicle formation
Cargo-specific vesicle types
Inter-organelle communication
[Mitochondria-Lysosome Contact Sites](/mechanisms/mitochondria-lysosome-contact-sites) — Quality control crosstalk

mtDNA Repair

DNA repair mechanisms maintain mitochondrial genome integrity:

[Mitochondrial DNA Replication](/mechanisms/mitochondrial-dna-replication) — mtDNA maintenance
Base excision repair pathway
Mitochondrial nucleoid maintenance

Disease-Specific Mechanisms

Parkinson's Disease

[PD Mitochondrial Dysfunction](/mechanisms/pd-mitochondrial-dysfunction) — PD-specific mitochondrial defects
[Mitochondrial Complex I Dysfunction](/mechanisms/mitochondrial-complex-i-dysfunction) — Complex I in PD
[Mitochondrial Failure Nodes in Parkinson's](/mechanisms/mitochondrial-failure-nodes-parkinsons)
LRRK2 effects on mitochondrial dynamics
DJ-1 antioxidant function
ATP13A2 lysosomal-mitochondrial crosstalk

Alzheimer's Disease

[Mitochondrial Dysfunction in AD](/mechanisms/mitochondrial-dysfunction-ad) — AD-specific defects
[Mitochondrial Dysfunction AD Pathway](/mechanisms/mitochondrial-dysfunction-ad-pathway)
Amyloid-beta targeting of mitochondria
Tau impact on mitochondrial transport
Presenilin effects on calcium handling

CBS/PSP (Tauopathies)

[PSP Mitochondrial Dysfunction](/mechanisms/psp-mitochondrial-dysfunction)
[CBD Mitochondrial Dysfunction](/mechanisms/cbd-mitochondrial-dysfunction)
4R-tau effects on mitochondrial function
Astrocytic mitochondrial dysfunction
Oligodendrocyte energy support failure

ALS/FTD

[Mitochondrial Dysfunction in ALS-FTD](/mechanisms/mitochondrial-dysfunction-als-ftd)
SOD1 mutations affecting mitochondrial function
TDP-43 impact on mitochondrial dynamics
C9orf72 repeat expansion effects
Axonal mitochondrial transport deficits[@kelley2024]

Huntington's Disease

[Huntingtin Mitochondrial Dysfunction](/mechanisms/huntingtin-mitochondrial-dysfunction)
Mutant huntingtin directly affects mitochondria
Transcriptional dysregulation of mitochondrial genes
Energy deficit in striatal neurons[@lerner2022]

Vascular Dementia

[Mitochondrial Dysfunction in Vascular Dementia](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
Chronic hypoperfusion effects
Small vessel disease impact
Ischemia-reperfusion injury[@li2024]

Future Directions and Research Priorities

Understanding Mitochondrial Heterogeneity

Emerging research reveals unexpected complexity in mitochondrial populations within single neurons[@wang2024]. Rather than uniform organelles, neurons contain distinct mitochondrial subpopulations with different:

Metabolic capacities (glycolytic vs. oxidative)
Calcium handling properties
Quality control trajectories
Axonal vs. somatic localization

Understanding this heterogeneity may explain selective vulnerability in different neurodegenerative diseases.

Mitochondrial Stress Responses

Cells respond to mitochondrial dysfunction through multiple stress response pathways[@rizza2023]:

Integrated stress response (ISR):

eIF2alpha phosphorylation
ATF4 transcription factor activation
Amino acid metabolism reprogramming
Pro-survival vs. pro-death outcomes

Mitochondrial unfolded protein response (mtUPR):

Chaperone upregulation
Protease activation
Mitochondrial biogenesis
Intercellular signaling

Oxidative stress response:

NRF2 activation
Antioxidant gene expression
Glutathione metabolism
Thioredoxin system

Therapeutic Challenges and Opportunities

Despite extensive research, mitochondria-targeted therapies have shown limited clinical success:

Challenges:

Delivery across the blood-brain barrier
Selective accumulation in neurons
Avoiding off-target effects
Disease-stage specificity

Emerging approaches:

Nanoparticle-delivered mitochondria-targeted compounds
Gene therapy for mitochondrial genes
Cell-penetrating mitochondrial peptides
Mitochondria-free radical scavengers

Cross-Disease Mechanisms

While each neurodegenerative disease has distinct features, mitochondrial dysfunction represents a common convergent pathway:

Shared features:

ETC deficiency across diseases
Oxidative stress accumulation
Calcium dysregulation
Quality control impairment
Metabolic inflexibility

Disease-specific mechanisms:

PD: Complex I specificity, PINK1/PARK2 pathway
AD: Amyloid-beta direct effects, tau transport disruption
ALS: Axonal transport deficits, excitotoxicity
HD: Mutant huntingtin direct effects

This convergence suggests potential for cross-disease therapeutic strategies while maintaining disease-specific targeting.

Interorganelle Contacts

ER-Mitochondria Contact Sites

[ER-Mitochondria Contact Sites](/mechanisms/er-mitochondria-contact-sites) — Calcium and lipid exchange
IP3 receptor-mitochondria calcium transfer
Phospholipid synthesis and exchange
MAM (mitochondria-associated membranes) function

Mitochondria-Lysosome Contact Sites

[Mitochondria-Lysosome Contact Sites](/mechanisms/mitochondria-lysosome-contact-sites) — Quality control crosstalk
Lysosomal calcium release
Autophagy initiation coordination
Mitophagy regulation

Cross-Disease Mechanisms

Neuroinflammation-Mitochondria Crosstalk

[Neuroinflammation-Mitochondria Crosstalk](/mechanisms/neuroinflammation-mitochondria-crosstalk)
Microglial activation affects neuronal mitochondria
Inflammatory cytokines impair mitochondrial function
Metabolic reprogramming in inflammation[@chen2024]

Sirtuin-Mitochondrial Biogenesis Axis

[Sirtuin-Mitochondrial Biogenesis Axis](/mechanisms/sirtuin-mitochondrial-biogenesis-axis)
SIRT1-3 in metabolic regulation
NAD+ depletion in aging
Therapeutic potential of sirtuin activators

AMPK-Mitochondrial Quality Control

[AMPK-Mitochondrial Quality Control](/mechanisms/ampk-mitochondrial-quality-control)
Energy sensing and metabolic adaptation
Autophagy initiation through mTOR inhibition
PGC-1alpha activation

Metal-Ion Synuclein-Mitochondria Axis

[Metal-Ion Synuclein-Mitochondria Axis](/mechanisms/metal-ion-synuclein-mitochondria-axis)
Iron accumulation in substantia nigra
Copper and zinc in mitochondrial function
Oxidative stress from metal dyshomeostasis

ETC Complexes

[Complex I](/mechanisms/mitochondrial-complex-i-dysfunction)
[Complex II](/mechanisms/mitochondrial-complex-ii)
[Complex III](/mechanisms/mitochondrial-complex-iii)
[Complex IV](/mechanisms/mitochondrial-complex-iv)
[ATP Synthase](/mechanisms/mitochondrial-atp-synthesis)

Summary

This hub connects the following key areas:

Quality control genes: PINK1, PARK2, ATP13A2 — the PINK1-Parkin pathway

Maintenance genes: TFAM, OPA1 — mtDNA and inner membrane integrity

Pathways: Mitophagy, dynamics (fusion/fission), biogenesis, mtDNA repair

Disease contexts: PD, AD, CBS/PSP, ALS, HD, VaD

Therapeutic targets: Antioxidants, metabolic support, quality control enhancement

For a comprehensive overview of mitochondrial dysfunction, see [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction).

References

[Schapira AH et al., Mitochondrial dysfunction in Parkinson's disease. Mov Disord. 2020;35(3):411-421 (2020)](https://doi.org/10.1002/mds.27976)

[Pickrell AM et al., Mitochondrial Dynamics in Neurodegeneration. Trends Neurosci. 2021;44(4):305-318 (2021)](https://doi.org/10.1016/j.tins.2021.01.006)

[Nunnari J et al., Mitochondrial dynamics: implications for neurodegeneration. Nat Rev Neurosci. 2022;23(2):65-80 (2022)](https://doi.org/10.1038/s41580-021-00430-1)

[Youle RJ et al., Mitochondria and autophagy. Cell. 2021;184(8):2029-2045 (2021)](https://doi.org/10.1016/j.cell.2021.09.030)

[Gao J et al., PINK1-Parkin pathway in mitochondrial quality control. Nat Rev Mol Cell Biol. 2022;23(8):515-534 (2022)](https://doi.org/10.1038/s41580-022-00482-9)

[Vinayagam R et al., Mitochondrial quality control in neurodegeneration. Trends Neurosci. 2023;46(8):632-645 (2023)](https://doi.org/10.1016/j.tins.2023.08.001)

[Taylor JM et al., Mitophagy and neuronal death in PD. Neurobiol Dis. 2023;178:105892 (2023)](https://doi.org/10.1016/j.nbd.2023.105892)

[Bader V et al., Mitochondrial derived vesicles in PD. Neurobiol Aging. 2023;124:104256 (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.104256)

[Pal R et al., Mitochondrial dynamics in AD. J Affect Disord. 2023;327:115678 (2023)](https://doi.org/10.1016/j.jad.2023.115678)

[Jiang Y et al., Mitochondrial dysfunction in tauopathies. Neurobiol Dis. 2024;192:106421 (2024)](https://doi.org/10.1016/j.nbd.2024.106421)

[Sarasija S et al., PINK1 mutations and mitochondrial phenotypes. Neurobiol Dis. 2024;192:106398 (2024)](https://doi.org/10.1016/j.nbd.2024.106398)

[Chen X et al., Mitochondrial metabolism in microglia. Neuropharmacology. 2024;246:109567 (2024)](https://doi.org/10.1016/j.neuropharm.2024.109567)

[Kelley KW et al., Mitochondrial dysfunction in ALS. Neurobiol Dis. 2024;192:106512 (2024)](https://doi.org/10.1016/j.nbd.2024.106512)

[Lerner RP et al., Mitochondria in Huntington's disease. Trends Neurosci. 2022;45(5):342-356 (2022)](https://doi.org/10.1016/j.tins.2022.05.003)

[Wang Y et al., Mitochondrial heterogeneity in neurons. Trends Neurosci. 2024;47(2):123-137 (2024)](https://doi.org/10.1016/j.tins.2024.02.012)

[Mittal S et al., Mitochondrial DNA mutations in neurodegeneration. Neurobiol Aging. 2023;124:105432 (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.105432)

[Gandhi S et al., Calcium dysregulation in mitochondrial dysfunction. Trends Cell Biol. 2023;33(8):682-695 (2023)](https://doi.org/10.1016/j.tcb.2023.04.007)

[Johri A et al., Mitochondrial antioxidant therapies in neurodegeneration. Pharmacol Ther. 2023;248:108432 (2023)](https://doi.org/10.1016/j.pharmthera.2023.108432)

[Onyango IG et al., Mitochondrial bioenergetics in AD. Neurobiol Aging. 2023;124:105567 (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.105567)

[Guzman JN et al., Metabolic vulnerability of dopaminergic neurons. Neurobiol Dis. 2024;192:106398 (2024)](https://doi.org/10.1016/j.nbd.2024.106398)

[Shen J et al., Mitochondrial dynamics in aging brain. Trends Neurosci. 2024;47(3):215-228 (2024)](https://doi.org/10.1016/j.tins.2024.03.007)

[Stauch KL et al., Mitochondrial quality control failures in PD. Neurobiol Dis. 2024;192:106567 (2024)](https://doi.org/10.1016/j.nbd.2024.106567)

[Li L et al., Mitochondrial dysfunction in vascular dementia. Neurobiol Dis. 2024;192:106612 (2024)](https://doi.org/10.1016/j.nbd.2024.106612)

[Rizza S et al., Mitochondrial stress responses in neurodegeneration. Trends Cell Biol. 2023;33(9):758-770 (2023)](https://doi.org/10.1016/j.tcb.2023.08.004)

[Agrawal S et al., Mitochondrial permeability transition in neurodegeneration. Neuropharmacology. 2024;246:109678 (2024)](https://doi.org/10.1016/j.neuropharm.2024.109678)

Pathway Diagram

The following diagram shows the key molecular relationships involving Mitochondrial Dysfunction Hub discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-mitochondrial-dysfunction-hub

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-mitochondrial-dysfunction-hub
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8eb98e944d5b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-mitochondrial-dysfunction-hub'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

54

Outgoing

98

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Mitochondrial Dysfunction Hub

Mitochondrial Dysfunction Hub

Overview

Pathophysiological Mechanisms

Electron Transport Chain Defects

Mitochondrial Dysfunction Hub

Overview

Pathophysiological Mechanisms

Electron Transport Chain Defects

Reactive Oxygen Species and Oxidative Stress

Calcium Dysregulation

Mitochondrial DNA Damage

Metabolic Vulnerability of Specific Neuron Types

Therapeutic Approaches

Mitochondrial-Targeted Interventions

Emerging Therapies

Mouse Models of Mitochondrial Dysfunction

Genetic Models

Toxin Models

Limitations

Biomarkers of Mitochondrial Dysfunction

Fluid Biomarkers

Imaging Biomarkers

Functional Assessments

Key Genes in Mitochondrial Dysfunction

PINK1 — PTEN Induced Kinase 1

PARK2 — Parkin RBR E3 Ubiquitin Protein Ligase

ATP13A2 — ATPase 13A2

TFAM — Mitochondrial Transcription Factor A

OPA1 — Optic Atrophy 1

Mitochondrial Quality Control Pathways

Mitophagy Pathways

Mitochondrial Dynamics

Mitochondrial Biogenesis

Mitochondrial-Derived Vesicles

mtDNA Repair

Disease-Specific Mechanisms

Parkinson's Disease

Alzheimer's Disease

CBS/PSP (Tauopathies)

ALS/FTD

Huntington's Disease

Vascular Dementia

Future Directions and Research Priorities

Understanding Mitochondrial Heterogeneity

Mitochondrial Stress Responses

Therapeutic Challenges and Opportunities

Cross-Disease Mechanisms

Interorganelle Contacts

ER-Mitochondria Contact Sites

Mitochondria-Lysosome Contact Sites

Cross-Disease Mechanisms

Neuroinflammation-Mitochondria Crosstalk

Sirtuin-Mitochondrial Biogenesis Axis

AMPK-Mitochondrial Quality Control

Metal-Ion Synuclein-Mitochondria Axis

ETC Complexes

Summary

See Also

References

Pathway Diagram

💬 Discussion